Studies, harm-reduction data, and usage reports — summarized for humans.
A new preprint using nationally representative PATH data (2022–2024) finds nicotine pouch initiation is heavily concentrated among people who already use other tobacco products — smokeless users were over 40 times more likely to start than non-users — while most adults never touch the category.
PATH Study wave 7 data on 29,705 US adults: 1.4% used nicotine pouches in the past 30 days, and pouch users skew 18–24, female and college-educated — a completely different profile than snus and smokeless tobacco users.
An updated scoping review in Nicotine & Tobacco Research covers 73 new pouch studies: US youth use hit 1.8%, adult sales tripled since 2021, high-strength pouches deliver more nicotine than cigarettes — and pouches remain considerably less toxic than cigarettes, with long-term effects still unknown.
An updated Georgetown-led scoping review adds 73 studies to its evidence base: pouches are considerably less toxic than cigarettes, higher-strength pouches deliver more nicotine than a cigarette, and the quit evidence remains thin.
New research shows menthol extends nicotine's effects on body temperature in rats for at least two hours. The finding adds to the debate over menthol's role in nicotine products.
Mark Holland has rejected industry calls to allow pouches in stores, keeping the products prescription-only despite arguments that legal retail access could undercut the illicit market.
An NIH- and FDA-funded team pulled 73 new studies into one review: youth use creeping up, adult use low, sales tripling — and stronger pouches delivering nicotine faster than cigarettes.
A randomized controlled study comparing cigarettes, heated tobacco, e-cigarettes, snus and nicotine pouches found inhaled products peak in 5–6 minutes while oral products take 36–39 — and the speed gap tracks with abuse liability.
A University of Sydney Matilda Centre survey of 1,848 Australian high school students found 3.5% had used nicotine pouches — and pouch use almost never came alone: 82% of pouch users had also vaped and 71% had smoked cigarettes. Males had nearly three times the odds of pouch use.
Shadow treasurer Angus Taylor and Nationals leader Matt Canavan have announced plans to legalise and regulate nicotine pouches in Australia, alongside an 80% tobacco excise cut and vape legalisation.
Swedish researchers found that snus users who switched to tobacco-free nicotine pouches saw their gum lesions heal within a month. The study tracked 22 daily snus users and measured changes in tissue thickness and inflammation.
A completed clinical trial compared nicotine absorption rates across four oral nicotine products, tracking blood levels and user experience in 27 regular pouch users confined to a clinic for four days.
Sweden's leading medical university warns that nicotine pouches — marketed as tobacco-free — deliver high doses of the 'toxic and highly addictive' substance, while research on long-term health effects remains limited.
White pouches show no evidence of gum damage in current research, unlike traditional snus
A 24-week randomised trial funded by Altria found that adult smokers who switched to on! nicotine pouches had significantly less gum inflammation, bleeding, and tooth staining than those who kept smoking. Every author is an Altria employee or paid consultant — so the caveats matter as much as the results.
Nicotine pouches are "tobacco-free" — but that doesn't mean safe. They're marketed as quit-smoking aids, but the FDA hasn't approved them for that. And the cancer question? Nobody knows yet. Here's what CDC, Cochrane, and the American Cancer Society actually say.
A review in Nature Reviews Cardiology maps a hierarchy of vascular harm across every nicotine product. Nicotine pouches sit at the bottom — least harmful among nicotine products — but impair endothelial function, raise oxidative stress and arterial stiffness, and have no long-term outcome data.
A peer-reviewed case series in BMC Oral Health documents two young men who developed receding gums and a white oral patch — leukoplakia — at the exact spot where they habitually parked their nicotine pouches. It is the first published clinical case report of leukoplakia associated with pouch use, though the lesion was never biopsy-confirmed.
A cross-sectional study of 42 male DZRT nicotine pouch users at King Abdulaziz University in Saudi Arabia found that over half had oral mucosal lesions, but lesion severity was not significantly associated with how long they had been using pouches. The study was small and underpowered, and 80% of users had been using for under a year.
A University of Gothenburg randomized crossover study found that dental plaque acidogenicity — a key cavity-risk marker — decreased over six weeks when snus users switched to ZYN nicotine pouches, even though cavity-causing bacteria levels went up.
A Karolinska Institutet and Folktandvården Stockholm clinical study of 272 young adults found that nicotine pouches cause more redness and ulcers than traditional snus, while snus causes more tissue thickening. Every ulcer seen in the study was in a pouch user.
Nicotine pouch cans label strength in milligrams per gram, milligrams per pouch, or vague terms like “extra strong.” A pouch labelled 20 mg/g holds 14 mg per pouch, not 20. Here’s why the labels are inconsistent, what science says about actual nicotine content, and how regulators are starting to fix it.
Three University of Gothenburg studies found adolescents who use nicotine — including tobacco-free nicotine pouches — report more anxiety and depression symptoms, with girls particularly vulnerable. A companion rat study showed nicotine altered the amygdala, most pronounced in females.
A BAT-funded study in BMC Chemistry measured 132 chemicals across 11 nicotine pouches, two snus products and cigarette-smoke data. Pouches came out with fewer detectable toxicants and over 90% lower levels than snus in most tests — but nine of the pouches tested were Velo, made by the funder.
A peer-reviewed review in Frontiers in Oral Health finds nicotine pouches remove the combustion that drives smoking-related oral cancer, but no long-term data exists to say what they mean for cancer risk. A separate UK dental-team update flags mucosal lesions and gum recession among users.
The first Cochrane review of oral nicotine pouches as a quitting aid found only four tiny studies covering 284 people — and rated its confidence in the findings as 'very low'. Here's what we actually know.
Professor Kerstin Brismar of Karolinska Institutet says the surge in white snus use among young women may be driving the parallel rise in type 2 diabetes. She expects confirming research soon.
The FDA just released Wave 8 of the PATH Study, the federal government's most comprehensive look at nicotine pouch usage in America. Here's what the data covers.
A Karolinska study of 272 young adults found receding gums in 45% of nicotine pouch users versus 6% of non-users — and pouches caused more gum irritation than snus. Here's what the research actually says, and what it doesn't.